Aclaris phase 2 atopic dermatitis trial fails primary endpoint

Aclaris Therapeutics (ACRS) reported that its Phase 2 trial for bosakitug in atopic dermatitis failed to meet primary and secondary endpoints. The drug was well tolerated, and the company plans to focus on other treatments, including ATI-052 and modzatinib, with Phase 2b trials scheduled.

Original reporting
Published Nov 16, 2026, 8:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 8:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ACRS
Bearish
high confidence
Mentioned
$ACRS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ACRSBearishMed
01

Why it matters

The failed Phase 2 trial removes a near‑term catalyst and may pressure the stock, though the company retains other pipeline candidates.

02

Market read

Trial failure is material news for ACRS and may affect biotech sentiment.

03

What to watch

The trial still demonstrated target engagement and safety, which could support future programs.

Relevance 8/10Novelty 8/10Timing: today

Background

Aclaris Therapeutics (NASDAQ:ACRS) is a clinical‑stage biopharma focused on immuno‑inflammatory diseases.

Company-level read

Ticker impact

$ACRSBearishHigh confidence
Context

Aclaris Therapeutics' Phase 2 ADMIRATION trial failed to meet primary and secondary endpoints.

Expected impact

downward pressure as investors price in the failed trial

Evidence & confidence

Phase‑2 failure removes near‑term upside and raises questions on pipeline viability.

Market effects

Biotech sector may see modest weakness as trial failures raise risk concerns.

US biotech stocks could dip in early trading.

Limited to investors tracking clinical‑stage pharma.

Counterpoint

If the company can pivot to its oral kinase program, the impact may be temporary.

Key entities

  • Aclaris Therapeutics Inc.

    Developer of anti‑TSLP antibody and oral kinase inhibitors.

  • Neal Walker

    Chief Executive Officer of Aclaris Therapeutics.

Related articles

$ACRSMedAI 8/10

Wedbush cuts Aclaris Therapeutics stock rating on trial miss

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral, cutting its price target to $3.00 from $8.00 after a Phase 2 trial failure. The stock is down 13% over the past week. Wedbush expects Aclaris to shift focus to eosinophilic esophagitis but notes growing competition. Other analysts have mixed views on ACRS's pipeline and potential.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$ACRSHighAI 8/10

Aclaris stock falls after atopic dermatitis trial fails

Aclaris Therapeutics (NASDAQ:ACRS) shares dropped 6% after its Phase 2 ADMIRATION trial for atopic dermatitis treatment failed to meet primary and secondary endpoints. The trial evaluated bosakitug (ATI-045), which showed target engagement but did not improve Eczema Area and Severity Index scores. The company remains focused on other treatments, including modzatinib (ATI-2138) for lichen planus, with a Phase 2b trial underway.

$ACRSHighAI 8/10

Aclaris Therapeutics’ mAb fails in Phase II eczema trial

Aclaris Therapeutics' Phase II trial of bosakitug for atopic dermatitis failed to meet primary and secondary endpoints, though the drug showed target engagement. The company remains focused on other treatments, including modzatinib and ATI-052. The atopic dermatitis market is projected to grow to $21.5bn by 2033, with key players like Sanofi and AbbVie.